Home › Funds › NEXTBio Capital Management LP › PCVX
NEXTBio Capital Management LP position in PCVX
VAXCYTE INC · Health Care
NEXTBio Capital Management LP reported holding 107,223 shares of PCVX (VAXCYTE INC) in its Q3 2026 13F filing — a position valued at US$6.1M, representing 2.66% of its reported portfolio and ranking #16 among its reported holdings. NEXTBio Capital Management LP has disclosed PCVX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How NEXTBio Capital Management LP's PCVX position evolved
NEXTBio Capital Management LP first disclosed a stake in PCVX in Q4 2025 at 95,485 shares (US$4.4M). The position peaked in Q2 2026 at 107,223 shares, worth US$6.2M. Across 4 filings, NEXTBio Capital Management LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 107,223 shares valued at US$6.1M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 95.48K | $4.41M | New |
| Q1 2026 | 95.22K | $5.53M | Hold |
| Q2 2026 | 107.22K | $6.23M | Add |
| Q3 2026 | 107.22K | $6.10M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PCVX and 13F data
PCVX (VAXCYTE INC) is a Health Care company. 33 other funds we track also report a position in PCVX — the largest reported positions include Jupiter Topco LLC (US$1.04B), Janus Henderson Group (US$960.2M), T. Rowe Price Investment Management, Inc. (US$709.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PCVX
- Jupiter Topco LLC 17.97M sh · $1.04B · Q2 2026
- Janus Henderson Group 16.58M sh · $960.23M · Q1 2026
- T. Rowe Price Investment Management, Inc. 12.21M sh · $709.62M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 11.47M sh · $667.02M · Q2 2026
- Deep Track Capital, LP 4.30M sh · $249.96M · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 3.28M sh · $186.60M · Q3 2026
- Kynam Capital Management, LP 2.92M sh · $169.88M · Q2 2026
- Caligan Partners LP 2.19M sh · $127.23M · Q2 2026
- Paradigm Biocapital Advisors LP 2.13M sh · $123.69M · Q2 2026
- Bellevue Group AG 1.97M sh · $114.63M · Q2 2026
- Maverick Capital 1.61M sh · $93.78M · Q2 2026
- MAVERICK CAPITAL LTD 1.61M sh · $93.78M · Q2 2026
More on NEXTBio Capital Management LP
FAQ
How long has NEXTBio Capital Management LP held PCVX?
NEXTBio Capital Management LP has disclosed PCVX holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is NEXTBio Capital Management LP's current position in PCVX?
As of Q3 2026, NEXTBio Capital Management LP holds 107.22K shares of PCVX (VAXCYTE INC), valued at $6.10M, representing 2.66% of its reported portfolio and ranking #16.
Has NEXTBio Capital Management LP been buying or selling PCVX?
In the latest 13F filing (Q3 2026), NEXTBio Capital Management LP held unchanged its position in PCVX. The position peaked in Q2 2026 at 107.22K shares.
Which other funds hold PCVX?
Other major institutional holders of PCVX include Jupiter Topco LLC, Janus Henderson Group, T. Rowe Price Investment Management, Inc., among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.